Treatments for respiratory distress (COVID and COPD) are limited, uncomfortable, and have safety concerns. There are 93 million treatments per year for respiratory distress worldwide representing a $6 Billion market.
Hespiro™, SaiOx's patented device, provides a safe and effective non-invasive treatment for respiratory distress.
*Sources:World Health Organization (WHO), Centers for Disease Control (CDC),NationalInstitute of Health (NIH)
COVID-19 statistics as of 09:11 on September 10, 2020